A Label-free Quantitative Proteomics Strategy to Identify E3 Ubiquitin Ligase Substrates Targeted to Proteasome Degradation*

The ubiquitin-proteasome system is a central mechanism for controlled proteolysis that regulates numerous cellular processes in eukaryotes. As such, defects in this system can contribute to disease pathogenesis. In this pathway, E3 ubiquitin ligases provide platforms for binding specific substrates, thereby coordinating their ubiquitylation and subsequent degradation by the proteasome. Despite the identification of many E3 ubiquitin ligases, the identities of their specific substrates are still largely unresolved. The ankyrin repeat-containing protein with a suppressor of cytokine signaling box 2 (ASB2) gene that we initially identified as a retinoic acid-response gene in acute promyelocytic leukemia cells encodes the specificity subunit of an E3 ubiquitin ligase complex that is involved in hematopoietic cell differentiation. We have recently identified filamin A and filamin B as the first ASB2 targets and shown that ASB2 triggers ubiquitylation and proteasome-mediated degradation of these proteins. Here a global quantitative proteomics strategy is provided to identify substrates of E3 ubiquitin ligases targeted to proteasomal degradation. Indeed we used label-free methods for quantifying proteins identified by shotgun proteomics in extracts of cells expressing wild-type ASB2 or an E3 ubiquitin ligase-defective mutant of ASB2 under the control of an inducible promoter. Measurements of spectral count and mass spectrometric signal intensity demonstrated a drastic decrease of filamin A and filamin B in myeloid leukemia cells expressing wild-type ASB2 compared with cells expressing an E3 ubiquitin ligase-defective mutant of ASB2. Altogether we provide an original strategy that enables identification of E3 ubiquitin ligase substrates that have to be degraded.

[1]  Raymond J. Deshaies,et al.  Function and regulation of cullin–RING ubiquitin ligases , 2005, Nature Reviews Molecular Cell Biology.

[2]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[3]  L. Kobari,et al.  Myeloblastin is a granulocyte colony-stimulating factor-responsive gene conferring factor-independent growth to hematopoietic cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Calderwood,et al.  ASB2 targets filamins A and B to proteasomal degradation. , 2008, Blood.

[5]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[6]  N. Itoh,et al.  ATRA‐regulated Asb‐2 gene induced in differentiation of HL‐60 leukemia cells , 2001, FEBS letters.

[7]  K. Resing,et al.  Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.

[8]  Z. Darżynkiewicz,et al.  ASB-2 Inhibits Growth and Promotes Commitment in Myeloid Leukemia Cells* , 2002, The Journal of Biological Chemistry.

[9]  J. Rowley,et al.  15/17 TRANSLOCATION, A CONSISTENT CHROMOSOMAL CHANGE IN ACUTE PROMYELOCYTIC LEUKAEMIA , 1977, The Lancet.

[10]  Jianping Jin,et al.  Identification of substrates for F-box proteins. , 2005, Methods in enzymology.

[11]  J. Yates,et al.  A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.

[12]  Ping Wang,et al.  Structure of a c-Cbl–UbcH7 Complex RING Domain Function in Ubiquitin-Protein Ligases , 2000, Cell.

[13]  E. Feener,et al.  Label-free Quantitative Analysis of One-dimensional PAGE LC/MS/MS Proteome , 2008, Molecular & Cellular Proteomics.

[14]  Jens M. Rick,et al.  Quantitative mass spectrometry in proteomics: a critical review , 2007, Analytical and bioanalytical chemistry.

[15]  A. Zelent,et al.  Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. , 1998, Blood.

[16]  T. Shaler,et al.  Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. , 2003, Analytical chemistry.

[17]  L. Campbell,et al.  The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. , 2007, Blood.

[18]  M. Scheffner,et al.  A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Arndt Benecke,et al.  ASB2 Is an Elongin BC-interacting Protein That Can Assemble with Cullin 5 and Rbx1 to Reconstitute an E3 Ubiquitin Ligase Complex* , 2005, Journal of Biological Chemistry.

[20]  Odile Burlet-Schiltz,et al.  Mascot File Parsing and Quantification (MFPaQ), a New Software to Parse, Validate, and Quantify Proteomics Data Generated by ICAT and SILAC Mass Spectrometric Analyses , 2007, Molecular & Cellular Proteomics.

[21]  Keiichi I Nakayama,et al.  VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. , 2004, Genes & development.

[22]  Yasuhiko Masuho,et al.  ASB proteins interact with Cullin5 and Rbx2 to form E3 ubiquitin ligase complexes , 2005, FEBS letters.

[23]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[24]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[25]  J. Licht,et al.  Translocations of the RARalpha gene in acute promyelocytic leukemia. , 2001, Oncogene.

[26]  D. Chelius,et al.  Identification and relative quantitation of protein mixtures by enzymatic digestion followed by capillary reversed-phase liquid chromatography-tandem mass spectrometry. , 2002, Analytical chemistry.

[27]  Martin Scheffner,et al.  Protein ubiquitination involving an E1–E2–E3 enzyme ubiquitin thioester cascade , 1995, Nature.

[28]  K. Nakayama,et al.  U-box proteins as a new family of ubiquitin ligases. , 2003, Biochemical and biophysical research communications.

[29]  C. Moog-Lutz,et al.  Myeloblastin is an Myb target gene: mechanisms of regulation in myeloid leukemia cells growth-arrested by retinoic acid. , 2001, Blood.

[30]  P. Couraud,et al.  JAML , a novel protein with characteristics of a junctional adhesion molecule , is induced during differentiation of myeloid leukemia cells , 2003 .

[31]  Jonathan D. Licht,et al.  Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .

[32]  R Berger,et al.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.

[33]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[34]  E. Sztul,et al.  Characterization and Dynamics of Aggresome Formation by a Cytosolic Gfp-Chimera✪ , 1999, The Journal of cell biology.

[35]  A. Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.

[36]  R. Kopito,et al.  Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.

[37]  J. Licht,et al.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. , 1999, Blood.